Lamivudine as a single-agent pharmaceutical-grade API is processed into 150 mg and 300 mg film-coated tablets for oral antiretroviral administration. The addition ratio is controlled on a per-unit basis rather than through a universal percentage: each tablet contains 150 mg or 300 mg of lamivudine, with release testing anchored to an assay window of 90.0–110.0% of the label claim under USP Lamivudine Tablets and uniformity of dosage units under USP <905>. The powder blend is manufactured in a 200 L bin blender at 12–18 rpm for 10–15 min; segregation is minimized when the API particle size distribution is kept with d90 below 250 µm. Precompression bulk density must be measured because lamivudine is a high-dose API and can generate punch capping if the active ratio exceeds roughly 40–50% w/w in brittle filler systems; if the API is received as micronized powder, the material is first dry granulated on a roller compactor at 8–12 kN/cm roll force and milled to 16–20 mesh before final blending. Core compression on a 45-station rotary tablet press at 60–80 rpm with a main compression force of 10–18 kN typically yields hardness of 60–90 N and friability under USP <1216> below 1.0%.

Aqueous film coating follows in a 48-inch perforated coating pan; the coating suspension contains hypromellose, polyethylene glycol, and titanium dioxide. Inlet air temperature is set at 60–70 °C and the spray rate is adjusted to keep product bed temperature between 40 °C and 45 °C; this balance prevents overwetting and logo bridging while yielding a 3–5% w/w weight gain. Downstream packaging with aluminum/aluminum cold-form blisters must control residual moisture below 2.0% because the core contains a superdisintegrant and may soften under high relative humidity. Industry compliance for the finished product is established under FDA 21 CFR 210 and 211, with elemental impurity limits per ICH Q3D and residual solvent thresholds per ICH Q3C. Terminal finished products are single-agent lamivudine film-coated tablets at 150 mg and 300 mg strengths for oral HIV therapy.

What Formulation Constraints Arise When Lamivudine Is Co-Compressed with Dolutegravir and Tenofovir Disoproxil Fumarate?

In fixed-dose combination tablets, lamivudine is added at 300 mg per unit with tenofovir disoproxil fumarate 300 mg and dolutegravir 50 mg per unit; this triple combination is processed as a layered or homogenized compression based on segregation risk. The downstream process typically begins with separate pre-blends because the API particle sizes and bulk densities differ: tenofovir disoproxil fumarate has poor flow and is densified through dry granulation, while lamivudine and dolutegravir may be wet granulated with a 5% w/w povidone binder solution in a 250 L high-shear granulator at an impeller speed of 120–180 rpm and chopper speed of 1500–3000 rpm. The wet mass is dried in a fluid-bed dryer at an inlet air temperature of 55–65 °C to a final loss-on-drying of 1.5–2.5%; the dried granulate is milled through a 1.0 mm screen. Compression on a 37-station rotary press must be run in contained isolation because of the occupational exposure limits of the integrase inhibitor; main compression force is set between 15 kN and 25 kN to maintain tablet hardness above 100 N.

Compliance is anchored to ICH Q8(R2) design space and FDA 21 CFR 211.110 in-process sampling; finished product assay must meet 90.0–110.0% for each API. Dissolution is performed using USP <711> with product-specific media and paddle speed; the fast-release behavior of lamivudine can mask slower-release fractions of the companion APIs, so a two-stage or media-pH gradient may be required to discriminate failed batches. The tablet mixture must also meet a pharmacopoeial uniformity limit of AV ≤ 15 under USP <905> across the batch. Table 1 compares three marketed fixed-dose patterns in which lamivudine is present under different co-API loads.

At an addition level of 150 mg or 300 mg per capsule, lamivudine is filled into hard gelatin or hypromellose capsule shells after a direct-blend or slugged granulation process. The final blend must meet a content uniformity acceptance value of AV ≤ 15 under USP <905>, and the filling operation on a dosator-type capsule machine at 50,000–80,000 capsules/hour is limited by powder flow rather than by API solubility. A fill mass of 450 mg containing 150 mg lamivudine corresponds to 33.3% w/w active; for the 300 mg strength, the fill mass is adjusted upward to 500–650 mg, depending on excipient density. Compliance is governed by 21 CFR 211 and ICH Q3D elemental impurity limits; terminal product type is an oral capsule used principally in clinical trial blinding, alternate supply, or patient-specific compounding where tablets are unsuitable.

Pediatric Oral Granule Reconstitution and Bitter-Masking Particle Coating

Lamivudine-containing granules for pediatric oral administration are produced to a reconstituted concentration of 10 mg/mL, equivalent to 1.0% w/v in the final liquid. The granular intermediate is manufactured by top-spray fluid-bed granulation in which lamivudine is blended with a water-soluble filler such as mannitol and a suspending agent such as xanthan gum; binder solution, typically povidone or hydroxypropyl cellulose at 5% w/w, is sprayed at 10–20 g/min onto a product bed maintained at 35–45 °C. The granulation endpoint is defined by particle size distribution: 90% of particles between 150 µm and 710 µm to ensure rapid reconstitution without floating. A secondary lipid-polymer coating is applied to suppress the bitter taste of lamivudine; this coating increases particle diameter by 15–25 µm and delays dissolution in artificial saliva by 30–60 seconds, which is sufficient for organoleptic masking but does not impair release in 0.1 N HCl medium.

Compliance is established under EMA/CHMP pediatric formulation guidance, ICH Q3B degradation product thresholds, and USP <905> for unit dose uniformity of the dry powder. The reconstituted suspension is filled into 100 mL HDPE bottles with child-resistant closures, and the terminal product type is an oral granule/powder for suspension for pediatric HIV or HBV treatment. Published data for the exact marketed granule composition is limited; in-house development batches should verify sedimentation volume and redispersibility after 7 days of storage at 25 °C/60% RH.

When Sterile Compounding Requires Lamivudine Injectable Solutions in Hospital Pharmacy Isolators

Injectable lamivudine is not a globally registered single-agent parenteral product; published data for this specific configuration is limited. Hospital central intravenous admixture services that prepare lamivudine infusions from pharmaceutical-grade API must operate under EU GMP Annex 1 and USP <797> pharmaceutical compounding standards. A typical experimental admixture concentration is 1.5 mg/mL, created by dissolving 150 mg lamivudine in 100 mL normal saline or dextrose 5% injection under aseptic conditions. The manufacturing sequence includes sterile filtration through a 0.22 µm polyethersulfone or polyvinylidene difluoride filter and terminal filling into type I borosilicate glass vials or polypropylene infusion bags. If terminal steam sterilization is employed, the formulation must withstand 121 °C for 15 min; otherwise the product is aseptically processed in an ISO 14644-1 Class 5 isolator.

Quality control for the injectable format demands bacterial endotoxin levels below USP <85> acceptance limits, sterility per USP <71>, and particulate matter counts meeting USP <788> for subvisible particles. The pH is adjusted to 5.0–7.0 with 0.1 N hydrochloric acid or sodium hydroxide, and osmolality is matched to blood using sodium chloride. Terminal product type is an injectable solution for institutional use only; because no harmonized pharmacopoeial monograph for lamivudine injection exists, each batch must be validated under ICH Q2(R2) for assay, purity, and preservative content if preservative is included in multidose containers.

The 100 mg Hepatitis B Monotherapy Core and Its Dissolution Boundary

Lamivudine for chronic hepatitis B is formulated as a 100 mg tablet; the lower active load permits direct compression without the high-dose segregation risks seen in HIV-strength tablets. The addition ratio in a 400 mg core is 25.0% w/w; using a 300 mg core gives 33.3% w/w. The process begins with a low-shear tumble blend of lamivudine with microcrystalline cellulose, sodium starch glycolate, and magnesium stearate; the lubricant is added at 0.5–1.0% w/w and mixed for 3–5 min to avoid over-lubrication. Compression on a 27-station rotary press at 40–60 rpm with a main compression force of 8–12 kN produces cores with hardness 40–70 N; film coating with hypromellose provides a 2–4% w/w weight gain.

The critical release attribute is dissolution: a product-specific USP <711> test with 900 mL of 0.1 N HCl and paddle speed 75 rpm typically requires not less than 80% dissolved at 30 min. Because lamivudine is highly soluble, batch failures often reflect tablet hardness or coating thickness rather than API solubility; hardness above 90 N or coating weight gain above 6% w/w may suppress early dissolution. Compliance includes USP <905>, ICH Q3D, and residual solvents testing under ICH Q3C; terminal product type is a film-coated tablet of 100 mg for oral hepatitis B therapy.